Curexsys

Curexsys Provides Proprietary Isolation Technology for Exosomes Based on Traceless Immunoaffinity Process. This process differs from commonly used antibody-based methods, enabling the company to overcome a key obstacle in exosome preparation: residual antibodies in the final product.Curexsys was co-founded by Herbert Stadler, a series of biotech entrepreneurs, and Jens Gruber, former head of the Medical RNA Biology group. Jens Gruber serves as the Chief Scientific Officer of Curexsys.